TARGETED GENETICS EXPECTS TO RECEIVE $4 MIL. IN NIAID SPIRAT GRANTS
TARGETED GENETICS EXPECTS TO RECEIVE $4 MIL. IN NIAID SPIRAT GRANTS for AIDS studies being conducted at the Fred Hutchinson Cancer Research Center over a four-year period, the Seattle-based gene therapy R&D firm announced Sept. 1. Targeted Genetics will use the funds to support its research into CD8 cytotoxic T lymphocytes and intracellular vaccines for HIV. The company and the cancer center will receive $1.3 mil. in funding for the first year.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth